Education
About Us
Working with TipRanks
Follow Us
RaySearch Laboratories AB Class B (RSLBF)
OTHER OTC:RSLBF
RSLBF Stock Chart & Stats
$23.58
$0.00(0.00%)
At close: 4:00 PM EST
$23.58
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$18.11 - $39.30
Previous CloseN/A
Volume27.00
Average Volume (3M)3.00
Market Cap
$714.27M
Enterprise Value$6.70B
Total Cash (Recent Filing)$407.30M
Total Debt (Recent Filing)$394.80M
Price to Earnings (P/E)28.5
Beta0.86
Next Earnings
Apr 29, 2026EPS Estimate
0.15Next Dividend Ex-DateN/A
Dividend Yield1.26%
Share Statistics
EPS (TTM)0.22
Shares Outstanding30,799,536
10 Day Avg. Volume0
30 Day Avg. Volume3
Financial Highlights & Ratios
PEG Ratio2.87
Price to Book (P/B)7.93
Price to Sales (P/S)5.81
P/FCF Ratio21.76
Enterprise Value/Market Cap9.38
Enterprise Value/Revenue4.98
Enterprise Value/Gross Profit5.74
Enterprise Value/Ebitda17.77
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.87
Revenue Forecast (FY)$159.32M
Bulls Say, Bears Say
Bulls Say
Recurring Revenue BaseA ~39% recurring support revenue share materially improves revenue predictability and reduces reliance on one-off license timing. This durable stream supports steady cash generation, planning visibility, margin stability and underpins the company’s upgraded dividend policy and medium-term investment capacity.
Strong Free Cash FlowHigh free cash flow that tracks closely to net income shows the business converts profits into cash sustainably. This strengthens funding for R&D, regulatory processes, dividends and potential buybacks, while providing buffer for operating seasonality or strategic investments over the next several quarters.
AI Adoption And Clinical MomentumLarge-scale AI usage and clinical milestones deliver a structural competitive edge: improved productivity for customers, faster plan workflows, and demonstrable clinical outcomes. These entrenched capabilities increase switching costs, support product differentiation and should help adoption over the medium term.
Bears Say
RayCare Adoption Lag / Regulatory TimingVery limited RayCare orders and dependence on regulatory clears (EU online adaptive, US 510(k), chemo module timing) mean expansion of a strategic platform is delayed. Slower regulatory rollout will constrain revenue diversification and the anticipated RayCare ramp for multiple quarters to years.
Rising LeverageAn increased debt-to-equity ratio and rising total debt reduce financial flexibility. With ongoing regulatory and commercialization investments needed, higher leverage raises refinancing and covenant risk and limits optionality for opportunistic M&A or larger buybacks during adverse cycles.
Gross-Margin PressureA material gross-margin decline suggests cost pressure or adverse mix shifts that can erode operating leverage. If persistent, this reduces the durability of current EBIT margins and constrains free cash flow expansion, making margin targets and higher shareholder distributions harder to sustain.
RaySearch Laboratories AB News
RSLBF FAQ
What was RaySearch Laboratories AB Class B’s price range in the past 12 months?
RaySearch Laboratories AB Class B lowest stock price was $18.11 and its highest was $39.30 in the past 12 months.
What is RaySearch Laboratories AB Class B’s market cap?
RaySearch Laboratories AB Class B’s market cap is $714.27M.
When is RaySearch Laboratories AB Class B’s upcoming earnings report date?
RaySearch Laboratories AB Class B’s upcoming earnings report date is Apr 29, 2026 which is in 53 days.
How were RaySearch Laboratories AB Class B’s earnings last quarter?
RaySearch Laboratories AB Class B released its earnings results on Feb 12, 2026. The company reported $0.217 earnings per share for the quarter, beating the consensus estimate of $0.17 by $0.047.
Is RaySearch Laboratories AB Class B overvalued?
According to Wall Street analysts RaySearch Laboratories AB Class B’s price is currently Overvalued.
Does RaySearch Laboratories AB Class B pay dividends?
RaySearch Laboratories AB Class B pays a Annually dividend of $0.315 which represents an annual dividend yield of 1.26%. See more information on RaySearch Laboratories AB Class B dividends here
What is RaySearch Laboratories AB Class B’s EPS estimate?
RaySearch Laboratories AB Class B’s EPS estimate is 0.15.
How many shares outstanding does RaySearch Laboratories AB Class B have?
RaySearch Laboratories AB Class B has 30,799,536 shares outstanding.
What happened to RaySearch Laboratories AB Class B’s price movement after its last earnings report?
RaySearch Laboratories AB Class B reported an EPS of $0.217 in its last earnings report, beating expectations of $0.17. Following the earnings report the stock price went down -4.534%.
Which hedge fund is a major shareholder of RaySearch Laboratories AB Class B?
Currently, no hedge funds are holding shares in RSLBF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
RaySearch Laboratories AB Class B
RaySearch Laboratories AB (publ), a medical technology company, develops software solutions for cancer treatment worldwide. It develops and markets RayStation, a treatment planning system for treatment activities, such as automated planning, adaptive therapy, multi-criteria optimization, fast and accurate dose computations, OAR dose reduction, robustness, machine learning, VMAT, IMRT, 3D-CRT, virtual simulation, electron beam therapy, tomotherapy, stereotactic, proton therapy, carbon ion therapy, and boron neutron capture therapy. The company also develops RayPlan, a treatment planning system for supporting a range of treatment planning activities for 3D-CRT, IMRT, VMAT, tomotherapy, and electron beam radiation therapy; and RayCare, an oncology information system to support cancer treatment activities. In addition, it offers RayCommand, a treatment control system that is compatible with various hardware models and supports advanced functionalities of treatment machines and software systems; and RayIntelligence, a cloud-based oncology analytics system that turns patient data into insights. Further, the company provides training courses related to its products. RaySearch Laboratories AB (publ) is headquartered in Stockholm, Sweden.
RSLBF Company Deck
RSLBF Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a broadly positive operational and commercial picture: record revenues, strong organic growth, improving profitability and cash position, significant clinical milestones and substantial AI adoption/use cases. Key negatives are material currency headwinds, a book-to-bill ratio below 1 and slower-than-desired traction for RayCare (partly tied to regulatory timing). Management expects margin improvement (target at least 25% for 2026) and a RayCare ramp in coming years, and has strengthened shareholder returns with a higher dividend and a 50% payout policy.View all RSLBF earnings summariesTechnical Analysis
Ownership Overview
―
Insiders
2.46% Mutual Funds
― Other Institutional Investors
89.53% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---